Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GW Pharmaceuticals reacquires full rights of develop Sativex in US
As a result, GW has now reacquired full ownership of the development and commercialization rights to the product in the U.S. market without making any upfront payment to
As a result, GW has now reacquired full ownership of the development and commercialization rights to the product in the U.S. market without making any upfront payment to
The Company’s Board of Directors has unanimously approved the transaction. Under the terms of the merger agreement, a subsidiary of Allergan will commence a cash tender offer to
Harpoon Therapeutics' TriTAC molecules are half-life extended and designed to simultaneously bind to cancer cells and T-cells, triggering those T-cells to attack the targeted cancer cells. These molecules
In connection with the investment, James Peyer, Managing Partner of Apollo Ventures, has joined Aeonian's Board of Directors. Aeonian is an early-stage company engaged in the discovery and
The deal will provide Fosun Pharma with the exclusive rights to develop and commercialize Ardelyx's lead product, tenapanor, in China for the treatment of patients with irritable bowel syndrome
The study has demonstrated enhanced PFS in patients treated with talazoparib compared against patients who received physician’s choice standard of care chemotherapy. Talazoparib is an investigational, oral and
NICE recommends lenvatinib, also known as kisplyx, be given in conjunction with another drug called everolimus. This drug-duo is recommended as an option for people who have previously
AP-002 is a nasally inhaled surfactant based on a combination of Lyomark's Alveofact® (bovine lung surfactant) and Aerogen's next generation "PDAP™" delivery technology. The partners expect AP-002 to
Cryotherapy is the general utilization of low temperatures in therapeutic treatment. It is utilized to cure a range of favorable and threatening tissue break, medically called as sores.
The companies will work together to advance TC BioPharm’s lead CAR-engineered gamma delta T cell program into clinical trials as well as on additional hematologic and solid tumor